AlphAIAlphAI — Financial news for AI agents
globenewswire.comSEP 291 min read$GOAI

Eva Live CEO David Boulette Continues Open Market Buying and Acquires Additional GOAI Shares

Eva Live Inc. (GOAI) CEO David Boulette bought 19,800 shares at $2.01 each, increasing his ownership to 23.2M shares. This follows a prior purchase of 18,478 shares at $2.03 each. Boulette cited confidence in the company's long-term potential and alignment with shareholders.

Original reporting
globenewswire.com
Published Sep 29, 2026, 1:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 5:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GOAI
Bullish
high confidence
Mentioned
$GOAI
Relevance
4/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$GOAIBullishLow
01

Why it matters

The disclosed purchases could be interpreted as a vote of confidence, possibly prompting short covering or modest buying.

02

Market read

Small insider purchase; limited immediate market impact but may influence sentiment.

03

What to watch

Potential that the CEO is accumulating ahead of undisclosed strategic developments.

Relevance 4/10Novelty 4/10Timing: after-hours disclosure today

Background

Eva Live Inc. (NASDAQ: GOAI) is an AI technology company. The CEO's recent purchases are part of ongoing insider buying activity.

Company-level read

Ticker impact

$GOAIBullishHigh confidence
Context

CEO David Boulette bought 19,800 shares at $2.01, raising his total to over 23.2 million shares, disclosed via a Form 4 filing.

Expected impact

likely modest buying pressure as investors view the purchase as a confidence signal

Evidence & confidence

Form 4 insider buying is a primary disclosure; although the dollar amount is small, the CEO's large stake reinforces alignment with shareholders.

Market effects

Sector

Minimal; reinforces confidence in AI sector but no broader impact.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The purchase size is negligible relative to market cap; may not move price.

Key entities

  • Executive
    David Boulette

    CEO of Eva Live Inc.

Read at source← All news

Related articles

JUL 21
$GOAIMed

Eva Live Targets A $3T Global Defense, Satellite And AI Infrastructure Opportunity With Proposed Acquisition Of Airbeam Wireless Technologies

Eva Live Inc. (NASDAQ: GOAI) said it signed a letter of intent to acquire a controlling 51% interest in Airbeam Wireless Technologies Inc., with an option for the remaining 49%. The deal values Airbeam at about $16 million and would add 260+ patents and 60GHz millimeter-wave connectivity technology, supporting Eva’s autonomous defense, AI communications, and satellite networking plans.

rfglobalnet.com3 min
JUL 20
$GOAIMed

EVA LIVE TARGETS A $3 TRILLION GLOBAL DEFENSE, SATELLITE AND AI INFRASTRUCTURE OPPORTUNITY WITH PROPOSED ACQUISITION OF AIRBEAM WIRELESS TECHNOLOGIES

Eva Live Inc. (NASDAQ: GOAI) said it signed a letter of intent to acquire a controlling 51% stake in Airbeam Wireless Technologies Inc., with an option for the remaining 49%. The deal values Airbeam at about $16 million and would give access to 260+ patents and 60GHz millimeter-wave connectivity tech, supporting Eva’s autonomous defense and AI communications plans.

itnewsonline.com4 min
JUN 10
$GOAIMed

Eva Live Shares Slip 4% Despite Proposed Psquared Acquisition

Eva Live (GOAI) shares fell 3.54% to $2.44 on Wednesday, down from a prior close of $2.53, despite the company signing a Letter of Intent to acquire Psquared Inc. Eva Live said Psquared has generated over $50 million in revenue in the past four years. The deal aims to expand its AI advertising platform with media-buying and multi-channel marketing capabilities, but remains subject to definitive agreements and closing conditions.

rttnews.com2 min
OCT 8
$ARGXMed

Stifel reiterates argenx stock Buy rating after trial stopped

Stifel maintained a Buy rating and $1,282 price target for argenx (ARGX) despite a Phase 3 trial halt for futility. The stock trades at $812.86, with a Fair Value estimate of $1,087.81. Analysts remain optimistic about other label expansions and upcoming data. Argenx reported 70% revenue growth and strong financial health. Other analysts have mixed ratings and price targets.

investing.com2 min